Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Mult Scler
; 26(13): 1729-1739, 2020 11.
Article
in En
| MEDLINE
| ID: mdl-31680631
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Multiple Sclerosis, Relapsing-Remitting
/
Multiple Sclerosis
Limits:
Humans
Language:
En
Journal:
Mult Scler
Journal subject:
NEUROLOGIA
Year:
2020
Type:
Article
Affiliation country:
United States